Seamless AI Integration AZmed's Rayvolve and Rayscan lines plug into existing radiology workflows (PACS/RIS) without major changes, enabling rapid deployment across multiple facilities. They already reach over 2,500 healthcare facilities in more than 55 countries, offering a broad base for a multi-site sales push. This creates an enterprise-scale AI adoption solution for hospital networks seeking minimal implementation friction and standardization.

CT AI Expansion In 2025 AZmed expanded with AZnod, the first CE-marked CT solution in Rayscan for lung nodule detection, broadening the portfolio beyond X-ray. This opens upsell opportunities to radiology departments investing in CT lung cancer screening and nodule management, and to cross-sell to existing Rayvolve users seeking end-to-end AI support across modalities.

Partnered Growth AZmed has established partnerships with GE Healthcare, NHS Wellbeing via WellbeingSoftware, and collaborations with Answer Digital and Radin Health, indicating a robust partner-led sales path. Leverage these relationships to access large hospital networks, procurement programs, and regional distributors, accelerating wins in targeted markets.

Regulatory Credibility With CE-marked modules and FDA-cleared indications, AZmed demonstrates regulatory readiness in EU and US markets, supported by funding activity. This reduces entry barriers for hospitals evaluating AI tools and enables integration with existing vendor ecosystems.

ROI Focus AZmed targets improving diagnostic confidence, reading speed, and operational performance to meet rising radiology demand. This supports ROI-focused pilots and trials emphasizing throughput gains, reduced repeat reads, and standardized reporting for large health systems and radiology groups.